Adherence of schizophrenia pharmacotherapy to published treatment recommendations: Patient, facility, and provider predictors

Schizophrenia Bulletin

Volumn 30, Issue 3, 2004, Pages 649-658

  Leslie, Douglas L ^a,b   Rosenheck, Robert A ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Academic health centers; Pharmacotherapy; Quality; Schizophrenia; Treatment guidelines

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; AGED; ARTICLE; COMORBIDITY; EDUCATION; FEMALE; HEALTH CARE FACILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 10344224586     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a007112     Document Type: Article

References (19)

1. Arana, G.W., and Rosenbaum, J.F. Handbook of Psychiatric Drug Therapy. Philadelphia, PA: Lippincott Williams & Wilkins, 2000.
2. Baldessarini, R.J.; Cohen, B.M.; and Teicher, M.H. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Archives of General Psychiatry, 45(1):79-91, 1988.
3. Chen, R.S.; Nadkarni, P.M.; Levin, RL.; Miller, P.L.; Erdos, J.; and Rosenheck, R.A. Using a computerized hospital database to monitor compliance of pharmacotherapeutic guidelines in the treatment of schizophrenia. Psychiatric Services, 51(6):791-794, 2000.
4. Citrome, L., and Volavka, J. Optimal dosing of atypical antipsychotics in adults: A review of the current evidence. Harvard Review of Psychiatry, 10(5):280-291, 2002.
5. Dixon, L.B.; Lehman, A.F.; and Levine, J. Conventional antipsychotic medications for schizophrenia. Schizophrenia Bulletin, 21(4):567-577, 1995.
6. Lehman, A.F.; Steinwachs, D.M.; and the Co-Investigators of the PORT Project. Translating research into practice: The Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophrenia Bulletin, 24(1):1-10, 1998.
7. Leslie, D., and Rosenheck, R. The effects of institutional fiscal stress on the use of atypical antipsychotic medications in the treatment of schizophrenia. Journal of Nervous and Mental Disease, 189(6):377-383, 2001a.
8. Leslie, D.L., and Rosenheck, R.A. Pharmacotherapeutic Treatment of Schizophrenia in the Department of Veterans Affairs: Prescribing Patterns and Guideline Adherence. West Haven, CT: Northeast Program Evaluation Center, 2000.
9. Leslie, D.L., and Rosenheck, R.A. Second Annual Report on Schizophrenia Pharmacotherapy in VA. West Haven, CT: Northeast Program Evaluation Center, 2001b.
10. Leslie, D.L., and Rosenheck, R.A. Use of pharmacy data to assess quality of pharmacotherapy for schizophrenia in a national health care system: Individual and facility predictors. Medical Care, 39(9):923-933, 2001c.
11. Liang, K., and Zeger, S. Longitudinal data analysis using generalized linear models. Biometrika, 73:13-22, 1986.
12. Lieberman, J., and Tasman, A. Psychiatric Drugs. Philadelphia, PA: W.B. Saunders, 2000.
13. Miller, A.L.; Chiles, J.A.; Chiles, J.K.; Crismon, M.L.; Rush, A.J.; and Shon, S.P. The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. Journal of Clinical Psychiatry, 60(10):649-657, 1999.
14. Milner, K.K., and Valenstein, M. A comparison of guidelines for the treatment of schizophrenia. Psychiatric Services, 53(7):888-890, 2002.
15. Nasrallah, H.A., and Smeltzer, D.J. Contemporary Diagnosis and Management of the Patient With Schizophrenia. Newtown, PA: Handbooks in Health Care, 2002.
16. Rosenheck, R.; Desai, R.; Steinwachs, D.; and Lehman, A. Benchmarking treatment of schizophrenia: A comparison of service delivery by the national government and by state and local providers. Journal of Nervous and Mental Disease, 188(4):209-216, 2000.
17. Rosenheck, R.; Greenberg, G.; and DiLella, D. Department of Veterans Affairs National Mental Health Program Performance Monitoring System: Fiscal Year 2000 Report. Northeast Program Evaluation Center, 2001.
18. Sernyak, M.J.; Leslie, D.L.; Alarcon, R.D.; Losonczy, M.F.; and Rosenheck, R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. American Journal of Psychiatry, 159(4):561-566, 2002.
19. Tauscher, J., and Kapur, S. Choosing the right dose of antipsychotics in schizophrenia: Lessons from neuroimaging studies. CNS Drugs, 15(9):671-678, 2001.